Sanofi (NASDAQ:SNY) Receives Average Recommendation of “Hold” from Brokerages

Sanofi (NASDAQ:SNY) has been assigned a consensus rating of “Hold” from the sixteen ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, three have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $49.50.

Several analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 29th. Royal Bank Of Canada began coverage on Sanofi in a research report on Tuesday, September 8th. They set a “sector perform” rating for the company. Morgan Stanley set a $49.00 price target on Sanofi in a research report on Wednesday, July 8th. Finally, HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th.

Hedge Funds Weigh In On Sanofi

Several institutional investors have recently bought and sold shares of SNY. Physician Wealth Advisors Inc. lifted its position in shares of Sanofi by 180.5% during the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after purchasing an additional 379 shares in the last quarter. Western Wealth Management LLC acquired a new position in shares of Sanofi in the first quarter valued at approximately $29,000. Leonteq Securities AG grew its holdings in shares of Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after purchasing an additional 297 shares in the last quarter. Fairway Wealth LLC purchased a new stake in Sanofi during the 1st quarter worth approximately $32,000. Finally, Annis Gardner Whiting Capital Advisors LLC increased its stake in Sanofi by 544.4% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock worth $34,000 after buying an additional 588 shares during the period. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Up 0.4%

NASDAQ SNY opened at $41.11 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64. The stock has a market capitalization of $99.67 billion, a P/E ratio of 21.52, a PEG ratio of 1.24 and a beta of 0.35. The firm’s 50-day moving average is $43.70 and its two-hundred day moving average is $44.26. Sanofi has a 12 month low of $40.65 and a 12 month high of $52.68.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 30th. The company reported $2.41 earnings per share for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The business had revenue of $13.36 billion during the quarter. During the same quarter in the prior year, the business earned $3.24 earnings per share. Sanofi’s revenue was up 16.0% on a year-over-year basis. On average, sell-side analysts anticipate that Sanofi will post 5.07 earnings per share for the current year.

About Sanofi

Sanofi is a global healthcare company headquartered in France that develops, manufactures and markets prescription medicines and vaccines. Its portfolio serves patients across areas including immunology, rare diseases, rare blood disorders, neurology, oncology and inflammatory conditions, as well as other specialty-care and general-medicine categories.

The company is also a major vaccine producer through its vaccines business, which supplies products for diseases such as influenza, polio, pertussis, meningitis and dengue.